Elena E. Luchinkina
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Elena E. Luchinkina has a total of 70 co-authors. Here are the top co-authors by number of shared publications:
- Ivan G. Gordeev
Pirogov Russian National Research Medical University
4 shared publications - Alesya A. Klimenko
Pirogov Russian National Research Medical University
3 shared publications - Gregory Pavlovich Arutyunov
Pirogov Russian National Research Medical University
3 shared publications - Vera N. Larina
Pirogov Russian National Research Medical University
3 shared publications Е. Е. Ильина
ФГАОУ ВО "Российский национальный исследовательский медицинский университет им. Н.И. Пирогова" Минздрава России (Пироговский Университет)
3 shared publications- A. V. Kapashin
Valenta Pharm JSC
2 shared publications
Latest Publications
- Open Access
- 10 November 2026
- Published by Silicea - Poligraf, LLC in Cardiovascular Therapy and Prevention
- Vol. 25 (5S) , 5158
Digital technologies in medical education
The article discusses digital technologies as an integral part of the modern higher medical education system. Attention is focused on electronic educational platforms, virtual patients, interactive clinical scenarios, multimedia simulators, and other tools that expand access to educational materials, standardize specific elements of training, and ensure the monitoring of academic performance. We analyzed the role of the digital educational event and the potential of its design within the pedagogical process, as well as the necessity of developing clinical AI literacy among students. Special attention is given to the use of electronic learning management systems at the final stage of training to build the practical readiness of General Medicine graduates. An example of using a digital educational environment as a tool for developing follow-up care skills in future physicians is presented.
- 10 November 2026
- Published by Silicea - Poligraf, LLC in Cardiovascular Therapy and Prevention
- Vol. 25 (5S) , 5158
Open AccessDigital technologies in medical education
The article discusses digital technologies as an integral part of the modern higher medical education system. Attention is focused on electronic educational platforms, virtual patients, interactive clinical scenarios, multimedia simulators, and other tools that expand access to educational materials, standardize specific elements of training, and ensure the monitoring of academic performance. We analyzed the role of the digital educational event and the potential of its design within the pedagogical process, as well as the necessity of developing clinical AI literacy among students. Special attention is given to the use of electronic learning management systems at the final stage of training to build the practical readiness of General Medicine graduates. An example of using a digital educational environment as a tool for developing follow-up care skills in future physicians is presented.
- 5 September 2026
- Published by Publishing House OKI in Antibiot Khimioter = Antibiotics and Chemotherapy
- Vol. 71 (5-6) , 34-44
Pharmacokinetic Parameters of a Combination Drug Containing Imidazolyl Ethylamide of Pentanedioic Acid and N,N'-bis-[2-(1,3-diazocyclopenta-2,4-dien-4-yl)ethyl] Malonic Acid Diamide in Healthy Volunteers
The aim of the study was to evaluate the pharmacokinetic parameters of escalating doses of a combination drug containing imidazolyl ethylamide of pentanedioic acid (IPA) and N,N'-bis-[2-(1,3-diazocyclopenta-2,4-dien-4-yl)ethyl] malonic acid diamide (XС9) in healthy volunteers. Material and methods . A phase I clinical study was conducted to investigate the pharmacokinetic parameters of the combination drug IPA + XС9 after single and subsequent multiple oral administration in healthy volunteers. Healthy volunteers were enrolled sequentially into three dose cohorts. Volunteers in Cohort 1 ( n = 6) received IPA + XС9 capsules containing 90 mg of IPA and 5 mg of XС9 (90 mg + 5 mg); volunteers in Cohort 2 ( n = 6) received capsules containing 90 mg IPA + 10 mg XC9 (90 mg + 10 mg); and volunteers in Cohort 3 ( n = 12) received capsules containing 90 mg IPA + 20 mg XC9 (90 mg + 20 mg). During the single-dose period, volunteers received one IPA + XC9 capsule corresponding to their dose cohort. Progression to multiple dosing and dose escalation were permitted only after the independent data monitoring committee (IDMC) reviewed the safety data. The washout period between the single-dose and multiple-dose periods was at least 7 days and no more than 21 days. Blood and urine samples were collected to determine the concentrations of the study drug’s active substances, IPA and XC9. Quantification of the active substances in plasma and urine was performed by high-performance liquid chromatography with tandem mass spectrometry (HPLC-MS/MS). Results . During the singledose period, a slight dose-dependent effect of XC9 on the plasma pharmacokinetic parameters of IPA was observed. At the highest studied dose of IPA + XС9 (90 mg + 20 mg), the C max and AUC 0–t for IPA were 301.37 ± 89.28 ng/mL and 1297.707 ± 469.535 ng × h/mL, respectively. During the single-dose period, the systemic exposure to XС9 in plasma increased in a dose-dependent manner. The highest C max and AUC 0–t values were observed at the 20 mg dose of XС9: 22.171 ± 8.644 ng/mL and 170.713 ± 48.346 ng × h/mL for C max and AUC 0–t , respectively. During the multiple-dose period, the C max, ss and AUC 0–τ for IPA after administration of the study drug at the 90 mg + 20 mg dose were 305.38 ± 120.43 ng/mL and 1426.108 ± 526.010 ng × h/mL, respectively, showing a weak dependence on the XС9 dose. The C max , ss and AUC 0–τ for XC9 at the maximum dose were 31.694 ± 8.491 ng/mL and 215.106 ± 59.871 ng × h/mL, respectively, demonstrating a dose-dependent increase. The pharmacokinetic parameters Ae (0–t) and R max , which reflect urinary excretion and maximum excretion rate, respectively, after a single dose of the study drug at the maximum dose were as follows: for IPA, 31390.317 ± 12193.271 µg and 5189.714 ± 2321.748 µg/h; and for XС9, 1054301.250 ± 452137.325 ng and 130015.240 ± 51728.662 ng/h. Regardless of the XС9 dose, the renal clearance of IPA remained constant during single dosing, ranging from 24 to 28 L/h, whereas the renal clearance of XС9 decreased with increasing doses (from 11.308 ± 4.111 L/h to 6.125 ± 1.430 L/h). In Cohort 3, during the multiple-dose period of IPA + XС9, the Ae (0–t) and R max values for IPA were 29563.529 ± 13674.235 µg and 4119.161 ± 2231.369 µg/h, and for XС9, they were 1671113.167 ± 733115.091 ng and 172748.875 ± 96684.186 ng/h, respectively. During the multiple-dose period, IPA renal clearance remained constant, ranging from 19 to 22 L/h, whereas XC9 renal clearance decreased with increasing doses. Conclusion . The study evaluated the plasma and urinary pharmacokinetics of IPA and XС9. A weak increase in IPA exposure was observed as the XС9 dose increased. Systemic exposure to XС9 increased in a dose-dependent manner in both the single-dose and multiple-dose periods. Regardless of the XС9 dose, the renal clearance of IPA remained constant, whereas the renal clearance of XС9 decreased with increasing doses. The results showed no significant pharmacokinetic interaction between IPA and XС9. Thus, the investigated combination of active substances meets current requirements for combination drug products.
- 5 September 2026
- Published by Publishing House OKI in Antibiot Khimioter = Antibiotics and Chemotherapy
- Vol. 71 (5-6) , 34-44
Pharmacokinetic Parameters of a Combination Drug Containing Imidazolyl Ethylamide of Pentanedioic Acid and N,N'-bis-[2-(1,3-diazocyclopenta-2,4-dien-4-yl)ethyl] Malonic Acid Diamide in Healthy Volunteers
The aim of the study was to evaluate the pharmacokinetic parameters of escalating doses of a combination drug containing imidazolyl ethylamide of pentanedioic acid (IPA) and N,N'-bis-[2-(1,3-diazocyclopenta-2,4-dien-4-yl)ethyl] malonic acid diamide (XС9) in healthy volunteers. Material and methods . A phase I clinical study was conducted to investigate the pharmacokinetic parameters of the combination drug IPA + XС9 after single and subsequent multiple oral administration in healthy volunteers. Healthy volunteers were enrolled sequentially into three dose cohorts. Volunteers in Cohort 1 ( n = 6) received IPA + XС9 capsules containing 90 mg of IPA and 5 mg of XС9 (90 mg + 5 mg); volunteers in Cohort 2 ( n = 6) received capsules containing 90 mg IPA + 10 mg XC9 (90 mg + 10 mg); and volunteers in Cohort 3 ( n = 12) received capsules containing 90 mg IPA + 20 mg XC9 (90 mg + 20 mg). During the single-dose period, volunteers received one IPA + XC9 capsule corresponding to their dose cohort. Progression to multiple dosing and dose escalation were permitted only after the independent data monitoring committee (IDMC) reviewed the safety data. The washout period between the single-dose and multiple-dose periods was at least 7 days and no more than 21 days. Blood and urine samples were collected to determine the concentrations of the study drug’s active substances, IPA and XC9. Quantification of the active substances in plasma and urine was performed by high-performance liquid chromatography with tandem mass spectrometry (HPLC-MS/MS). Results . During the singledose period, a slight dose-dependent effect of XC9 on the plasma pharmacokinetic parameters of IPA was observed. At the highest studied dose of IPA + XС9 (90 mg + 20 mg), the C max and AUC 0–t for IPA were 301.37 ± 89.28 ng/mL and 1297.707 ± 469.535 ng × h/mL, respectively. During the single-dose period, the systemic exposure to XС9 in plasma increased in a dose-dependent manner. The highest C max and AUC 0–t values were observed at the 20 mg dose of XС9: 22.171 ± 8.644 ng/mL and 170.713 ± 48.346 ng × h/mL for C max and AUC 0–t , respectively. During the multiple-dose period, the C max, ss and AUC 0–τ for IPA after administration of the study drug at the 90 mg + 20 mg dose were 305.38 ± 120.43 ng/mL and 1426.108 ± 526.010 ng × h/mL, respectively, showing a weak dependence on the XС9 dose. The C max , ss and AUC 0–τ for XC9 at the maximum dose were 31.694 ± 8.491 ng/mL and 215.106 ± 59.871 ng × h/mL, respectively, demonstrating a dose-dependent increase. The pharmacokinetic parameters Ae (0–t) and R max , which reflect urinary excretion and maximum excretion rate, respectively, after a single dose of the study drug at the maximum dose were as follows: for IPA, 31390.317 ± 12193.271 µg and 5189.714 ± 2321.748 µg/h; and for XС9, 1054301.250 ± 452137.325 ng and 130015.240 ± 51728.662 ng/h. Regardless of the XС9 dose, the renal clearance of IPA remained constant during single dosing, ranging from 24 to 28 L/h, whereas the renal clearance of XС9 decreased with increasing doses (from 11.308 ± 4.111 L/h to 6.125 ± 1.430 L/h). In Cohort 3, during the multiple-dose period of IPA + XС9, the Ae (0–t) and R max values for IPA were 29563.529 ± 13674.235 µg and 4119.161 ± 2231.369 µg/h, and for XС9, they were 1671113.167 ± 733115.091 ng and 172748.875 ± 96684.186 ng/h, respectively. During the multiple-dose period, IPA renal clearance remained constant, ranging from 19 to 22 L/h, whereas XC9 renal clearance decreased with increasing doses. Conclusion . The study evaluated the plasma and urinary pharmacokinetics of IPA and XС9. A weak increase in IPA exposure was observed as the XС9 dose increased. Systemic exposure to XС9 increased in a dose-dependent manner in both the single-dose and multiple-dose periods. Regardless of the XС9 dose, the renal clearance of IPA remained constant, whereas the renal clearance of XС9 decreased with increasing doses. The results showed no significant pharmacokinetic interaction between IPA and XС9. Thus, the investigated combination of active substances meets current requirements for combination drug products.
- Open Access
- 13 August 2026
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 31 (6) , 6928
Cardiovascular-renal-hepatic-metabolic syndrome. Teaching strategy in higher education
Physician training requires a unified approach to the content of educational programs across the country’s various medical universities in order to standardize the volume of knowledge that underlies professional skills, abilities, and competencies. To improve the preparation of medical students for practice, creation of a unified educational program for studying the interdisciplinary concept of cardiovascular-renal-hepatic-metabolic (CRHM) syndrome within the General Medicine program is discussed. This article presents methodological materials allowing pedagogical explanation of the concept, pathogenesis, characteristics of cardiometabolic risk factors, and individual components of CHRM syndrome in fundamental and clinical departments using the end-to-end learning principle. In this regard, the role of fundamental disciplines lies in shaping the curriculum in accordance with the needs of clinical practice. Special attention is given to teaching diagnostic criteria for the syndrome and a set of personalized preventive measures depending on the stage and phenotype of CHRM syndrome. It is proposed to emphasize the transition from target organs to a unified metabolic phenotype, taking into account the multi-vector nature of CHRM syndrome processes. The inclusion of the CHRM syndrome in the curricula of the Oncology, Neurology, Rheumatology, and Obstetrics and Gynecology disciplines appears promising, allowing future practicing physicians to perceive this concept holistically and systemically.
- 13 August 2026
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 31 (6) , 6928
Open AccessCardiovascular-renal-hepatic-metabolic syndrome. Teaching strategy in higher education
Physician training requires a unified approach to the content of educational programs across the country’s various medical universities in order to standardize the volume of knowledge that underlies professional skills, abilities, and competencies. To improve the preparation of medical students for practice, creation of a unified educational program for studying the interdisciplinary concept of cardiovascular-renal-hepatic-metabolic (CRHM) syndrome within the General Medicine program is discussed. This article presents methodological materials allowing pedagogical explanation of the concept, pathogenesis, characteristics of cardiometabolic risk factors, and individual components of CHRM syndrome in fundamental and clinical departments using the end-to-end learning principle. In this regard, the role of fundamental disciplines lies in shaping the curriculum in accordance with the needs of clinical practice. Special attention is given to teaching diagnostic criteria for the syndrome and a set of personalized preventive measures depending on the stage and phenotype of CHRM syndrome. It is proposed to emphasize the transition from target organs to a unified metabolic phenotype, taking into account the multi-vector nature of CHRM syndrome processes. The inclusion of the CHRM syndrome in the curricula of the Oncology, Neurology, Rheumatology, and Obstetrics and Gynecology disciplines appears promising, allowing future practicing physicians to perceive this concept holistically and systemically.
- Open Access
- 18 December 2025
- Published by Publishing House ABV Press in The Clinician
- Vol. 19 (3) , 65-72
Training of primary care doctors to perform comprehensive medical services to combat veterans
Currently, comprehensive medical care for combat veterans on the part of primary care doctors is an important problem. To improve the unified teaching strategy in medical universities for preparation of highly qualified specialists, the main questions of the training process of students studying the general medicine specialty are discussed. The article presents points of view of psychiatrists, psychologists, internal medicine doctors, ophthalmologists, dermatologists, and proposals on optimization of continuity of teaching how to manage patients with post-traumatic stress disorder and how to improve communication skills of future doctors during caring for patients with this acute emotional disorder. To improve preparedness of medical students to apply knowledge in clinical practice, the experts focus on the classical manifestations of post-traumatic stress disorder and psychosomatic disorders, teaching systemic approach to patients’ needs with focus on communication during outpatient appointments, discussion of combat stress target organs. During comprehensive discussion, the experts concluded that it is necessary to strengthen interactions between clinical and scientific departments of medical universities to study the role of stress in stepwise development of long-term consequences of stress-induced somatic pathology, to increase attention to details in communication between doctors and patients with post-traumatic stress disorder, to introduce problems of outpatient observation of combat veterans into the summer working practice of 5th year students training in general medicine. Regular updates of the training materials will help to better understand the problem of post-traumatic stress disorder and prepare graduates for performing qualified and rounded medical services to combat veterans.
- 18 December 2025
- Published by Publishing House ABV Press in The Clinician
- Vol. 19 (3) , 65-72
Open AccessTraining of primary care doctors to perform comprehensive medical services to combat veterans
Currently, comprehensive medical care for combat veterans on the part of primary care doctors is an important problem. To improve the unified teaching strategy in medical universities for preparation of highly qualified specialists, the main questions of the training process of students studying the general medicine specialty are discussed. The article presents points of view of psychiatrists, psychologists, internal medicine doctors, ophthalmologists, dermatologists, and proposals on optimization of continuity of teaching how to manage patients with post-traumatic stress disorder and how to improve communication skills of future doctors during caring for patients with this acute emotional disorder. To improve preparedness of medical students to apply knowledge in clinical practice, the experts focus on the classical manifestations of post-traumatic stress disorder and psychosomatic disorders, teaching systemic approach to patients’ needs with focus on communication during outpatient appointments, discussion of combat stress target organs. During comprehensive discussion, the experts concluded that it is necessary to strengthen interactions between clinical and scientific departments of medical universities to study the role of stress in stepwise development of long-term consequences of stress-induced somatic pathology, to increase attention to details in communication between doctors and patients with post-traumatic stress disorder, to introduce problems of outpatient observation of combat veterans into the summer working practice of 5th year students training in general medicine. Regular updates of the training materials will help to better understand the problem of post-traumatic stress disorder and prepare graduates for performing qualified and rounded medical services to combat veterans.
- Open Access
- 10 May 2023
- Published by Moscow Regional Research and Clinical Institute (MONIKI) in Almanac of Clinical Medicine
- Vol. 51 (1) , 53-58
Osteopontin in patients with chronic obstructive pulmonary disease and coronary heart disease
Background: Osteopontin is a protein expressed by various cell types, such as endothelial and epithelial cells, osteoclasts, hepatocytes, smooth muscle cells, activated macrophages, and T-cells. Cardiomyocytes, heart fibroblasts, endothelial cells of coronary arteries express osteopontin in response to hypoxia, inflammation, toxic factors, mechanical strain, and other stimuli. Aim: To study osteopontin levels in patients with chronic obstructive pulmonary disease (COPD) depending on concomitant ischemic heart disease (IHD), to identify an association between osteopontin levels with severity of COPD and functional lung test parameters. Materials and methods: This open-label, prospective, non-randomized comparative study with parallel groups included 99 patients with COPD grades AD by GOLD, with 49 of them having confirmed comorbid stable IHD. Serum osteopontin levels were measured by immunoenzyme assay (Human Osteopontin Platinum ELISA; Bender MedSystems, Austria). The data is given as medians and quartiles (Me [Q1; Q3]). In all patients we performed functional lung tests with bronchodilation, a 6-minute walking test, BODE index assessment, as well as CAT and mMRC questionnaires were used. Results: In the patients with COPD and IHD, the osteopontin levels were higher than in the patients with COPD without IHD (85.55 [46.86; 110.91] vs 55.43 [20.76; 89.64] ng/mL, respectively; p = 0.027). Osteopontin levels in the patients with all COPD grades and IHD were higher than in those without IHD, but the difference was significant only in GOLD grade B patients (91.28 [73.04; 110.91] vs 37.81 [22.54; 82.95] ng/mL, respectively, р = 0.028) and GOLD grade D patients (80.79 [34.65; 111.11] vs 37.46 [13.32; 109.5] ng/mL, respectively, р = 0.027). Conclusion: A significant increase of osteopontin levels in comorbid patients with COPD and stable IHD found in this study has not been previously known. It is necessary to perform further studies to identify a threshold level of osteopontin predictive of the risk of COPD exacerbations or cardiovascular events. This would help to improve medical treatment of COPD patients, as well as to identify the risk groups.
- 10 May 2023
- Published by Moscow Regional Research and Clinical Institute (MONIKI) in Almanac of Clinical Medicine
- Vol. 51 (1) , 53-58
Open AccessOsteopontin in patients with chronic obstructive pulmonary disease and coronary heart disease
Background: Osteopontin is a protein expressed by various cell types, such as endothelial and epithelial cells, osteoclasts, hepatocytes, smooth muscle cells, activated macrophages, and T-cells. Cardiomyocytes, heart fibroblasts, endothelial cells of coronary arteries express osteopontin in response to hypoxia, inflammation, toxic factors, mechanical strain, and other stimuli. Aim: To study osteopontin levels in patients with chronic obstructive pulmonary disease (COPD) depending on concomitant ischemic heart disease (IHD), to identify an association between osteopontin levels with severity of COPD and functional lung test parameters. Materials and methods: This open-label, prospective, non-randomized comparative study with parallel groups included 99 patients with COPD grades AD by GOLD, with 49 of them having confirmed comorbid stable IHD. Serum osteopontin levels were measured by immunoenzyme assay (Human Osteopontin Platinum ELISA; Bender MedSystems, Austria). The data is given as medians and quartiles (Me [Q1; Q3]). In all patients we performed functional lung tests with bronchodilation, a 6-minute walking test, BODE index assessment, as well as CAT and mMRC questionnaires were used. Results: In the patients with COPD and IHD, the osteopontin levels were higher than in the patients with COPD without IHD (85.55 [46.86; 110.91] vs 55.43 [20.76; 89.64] ng/mL, respectively; p = 0.027). Osteopontin levels in the patients with all COPD grades and IHD were higher than in those without IHD, but the difference was significant only in GOLD grade B patients (91.28 [73.04; 110.91] vs 37.81 [22.54; 82.95] ng/mL, respectively, р = 0.028) and GOLD grade D patients (80.79 [34.65; 111.11] vs 37.46 [13.32; 109.5] ng/mL, respectively, р = 0.027). Conclusion: A significant increase of osteopontin levels in comorbid patients with COPD and stable IHD found in this study has not been previously known. It is necessary to perform further studies to identify a threshold level of osteopontin predictive of the risk of COPD exacerbations or cardiovascular events. This would help to improve medical treatment of COPD patients, as well as to identify the risk groups.
- 6 May 2021
- Published by Publishing House OKI in Antibiot Khimioter = Antibiotics and Chemotherapy
- Vol. 66 (1-2) , 19-25
Pharmacokinetics of Pentanedioic Acid Imidazolyl Ethanamide in Healthy Volunteers
Relevance. Pentanedioic acid imidazolyl ethanamide (PAIE) has been used clinically as an antiviral agent for a long time, however, there is no information in the available literature concerning the dependence of PAIE pharmacokinetics on isoenzymes polymorphism of the cytochrome P450 system (CYP), as well as on the variability of pharmacokinetic parameters in humans. The aim of the study is to determine the main pharmacokinetic parameters of PAIE in healthy volunteers and to assess the contribution of polymorphism of CYP P450 isoenzymes to the variability of pharmacokinetic parameters.Material and methods. The study included 12 healthy volunteers (5 men and 7 women) of the Caucasian race, who took In[1]gavirin® at a dose of 180 mg (2 capsules of 90 mg) on an empty stomach during two dosing periods, separated by a 7-day washout period. Determination of PAIE concentration in blood plasma and urine samples was carried out by high-performance liquid chromatography–mass spectrometry. Polymorphism of CYP genes was analyzed using the polymerase chain re[1]action method in order to analyze the pharmacogenetic features of PAIE metabolism in volunteers during the study.Results. After oral administration, PAIE quickly reached the systemic circulation: the maximum concentration of 578.88±145.21 ng/ml was observed after about 2 hours. Pharmacokinetic parameters of PAIE did not show high intraindividual variability and did not depend on polymorphism of isoenzymes CYP1A1, CYP2C9, and CYP2D6. Within 48 hours after the administration of the studied drug, about half of the taken dose of PAIE was excreted in the urine unchanged, which indicates a significant contribution of the kidneys to the elimination of PAIE. The only adverse event registered in 1 volunteer was a clinically insignificant decrease in the level of leukocytes, which did not require medical intervention and was resolved without consequences.Conclusion. PAIE is characterized by predictable pharmacokinetics, low intraindividual variability of pharmacokinetic parameters, and a favorable safety profile.
- 6 May 2021
- Published by Publishing House OKI in Antibiot Khimioter = Antibiotics and Chemotherapy
- Vol. 66 (1-2) , 19-25
Pharmacokinetics of Pentanedioic Acid Imidazolyl Ethanamide in Healthy Volunteers
Relevance. Pentanedioic acid imidazolyl ethanamide (PAIE) has been used clinically as an antiviral agent for a long time, however, there is no information in the available literature concerning the dependence of PAIE pharmacokinetics on isoenzymes polymorphism of the cytochrome P450 system (CYP), as well as on the variability of pharmacokinetic parameters in humans. The aim of the study is to determine the main pharmacokinetic parameters of PAIE in healthy volunteers and to assess the contribution of polymorphism of CYP P450 isoenzymes to the variability of pharmacokinetic parameters.Material and methods. The study included 12 healthy volunteers (5 men and 7 women) of the Caucasian race, who took In[1]gavirin® at a dose of 180 mg (2 capsules of 90 mg) on an empty stomach during two dosing periods, separated by a 7-day washout period. Determination of PAIE concentration in blood plasma and urine samples was carried out by high-performance liquid chromatography–mass spectrometry. Polymorphism of CYP genes was analyzed using the polymerase chain re[1]action method in order to analyze the pharmacogenetic features of PAIE metabolism in volunteers during the study.Results. After oral administration, PAIE quickly reached the systemic circulation: the maximum concentration of 578.88±145.21 ng/ml was observed after about 2 hours. Pharmacokinetic parameters of PAIE did not show high intraindividual variability and did not depend on polymorphism of isoenzymes CYP1A1, CYP2C9, and CYP2D6. Within 48 hours after the administration of the studied drug, about half of the taken dose of PAIE was excreted in the urine unchanged, which indicates a significant contribution of the kidneys to the elimination of PAIE. The only adverse event registered in 1 volunteer was a clinically insignificant decrease in the level of leukocytes, which did not require medical intervention and was resolved without consequences.Conclusion. PAIE is characterized by predictable pharmacokinetics, low intraindividual variability of pharmacokinetic parameters, and a favorable safety profile.